Phathom Pharmaceuticals Inc

Leading Innovators in GI Disorder Treatments 2021 - North America
Winners image
<p>Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. Our lead asset, vonoprazan, is a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the US, Europe, and Canada in in over 30 years..</p>